-Jag Mohan Thaken India is uniquely positioned to capitalise on a global genomics revolution and a looming $300 billion patent expiry wave that is driving an aggressive wave of biopharma acquisitions. Reports say India hosts more WHOcertified pharmaceutical manufacturing plants than any other country on earth and for three decades, the model has been consistent.
